Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases.

Okita Y, Narita Y, Suzuki T, Arita H, Yonemori K, Kinoshita T, Fujiwara Y, Tsuda H, Komoike Y, Nakagawa H, Tamaki Y, Tomita Y, Shibui S, Maruno M.

Mol Clin Oncol. 2013 Nov;1(6):995-1001. Epub 2013 Jul 29.

2.

Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.

Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK.

Oncologist. 2015 May;20(5):466-73. doi: 10.1634/theoncologist.2014-0107. Epub 2015 Mar 23.

3.

Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM.

Ann Oncol. 2008 Jul;19(7):1242-8. doi: 10.1093/annonc/mdn036. Epub 2008 Mar 11.

PMID:
18334512
4.

Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.

Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, Saji S, Iwata H.

Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21.

PMID:
25528021
5.

Receptor conversion in distant breast cancer metastases.

Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ.

Breast Cancer Res. 2010;12(5):R75. doi: 10.1186/bcr2645. Epub 2010 Sep 23.

6.

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, Kümler I, Nielsen DL.

Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5. Review.

PMID:
23481218
7.

Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.

Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y.

Ann Oncol. 2016 Mar;27(3):480-7. doi: 10.1093/annonc/mdv611. Epub 2015 Dec 23.

PMID:
26704052
8.

Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.

Subramaniam S, Bhoo-Pathy N, Taib NA, Tan GH, See MH, Jamaris S, Ho GF, Looi LM, Yip CH.

World J Surg. 2015 Oct;39(10):2450-8. doi: 10.1007/s00268-015-3133-2.

PMID:
26138872
9.

Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.

Zhang Q, Chen J, Yu X, Cai G, Yang Z, Cao L, Hu C, Guo X, Sun J, Chen J.

Breast Cancer. 2016 Sep;23(5):732-9. doi: 10.1007/s12282-015-0631-x. Epub 2015 Aug 13.

PMID:
26267412
10.

Brain metastasis in breast cancer: a comprehensive literature review.

Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B.

J Neurooncol. 2016 May;127(3):407-14. doi: 10.1007/s11060-016-2075-3. Epub 2016 Feb 24. Review.

PMID:
26909695
11.

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.

Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group.

BMC Cancer. 2016 Jul 25;16:522. doi: 10.1186/s12885-016-2587-4.

12.

Breast cancer subtypes and survival in patients with brain metastases.

Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J.

Breast Cancer Res. 2008;10(1):R20. doi: 10.1186/bcr1870. Epub 2008 Feb 28.

13.

Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.

Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y.

Breast Cancer. 2014 Sep;21(5):563-70. doi: 10.1007/s12282-012-0424-4. Epub 2012 Oct 30.

PMID:
23108629
14.

Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.

Zurawska U, Baribeau DA, Giilck S, Victor C, Gandhi S, Florescu A, Verma S.

Curr Oncol. 2013 Dec;20(6):e539-45. doi: 10.3747/co.20.1523.

15.

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.

Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525. Epub 2013 Dec 18.

16.

89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA.

Clin Nucl Med. 2017 Sep 1. doi: 10.1097/RLU.0000000000001820. [Epub ahead of print]

PMID:
28872549
17.

Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.

Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I.

Breast Cancer Res. 2012 May 23;14(3):R82.

18.

Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.

Takada M, Higuchi T, Tozuka K, Takei H, Haruta M, Watanabe J, Kasai F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Ogawa S, Kaneko Y.

BMC Cancer. 2013 May 16;13:241. doi: 10.1186/1471-2407-13-241.

19.

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.

Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA.

Breast Cancer Res. 2012 May 23;14(3):R83.

20.

Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.

Rao PS, Labhart M, Mayhew SL, Thirumala S, Rao US.

Tumour Biol. 2014 Jul;35(7):7267-73. doi: 10.1007/s13277-014-1979-9. Epub 2014 Apr 29.

PMID:
24777335

Supplemental Content

Support Center